002317 众生药业
已收盘 05-08 15:00:00
资讯
新帖
简况
众生药业涨10.00%,开源证券一周前给出“买入”评级
证券之星 · 05-08 16:28
众生药业涨10.00%,开源证券一周前给出“买入”评级
众生药业(002317)披露控股子公司ZSP1601片IIb期临床试验初步结果,5月7日股价上涨9.98%
证券之星 · 05-07 22:03
众生药业(002317)披露控股子公司ZSP1601片IIb期临床试验初步结果,5月7日股价上涨9.98%
众生药业最新公告:MASH创新药ZSP1601片IIb期临床试验结果积极
证券之星 · 05-07 19:39
众生药业最新公告:MASH创新药ZSP1601片IIb期临床试验结果积极
今日众生药业(002317)涨停分析:创新药商业化+业绩增长+财务优化驱动
证券之星 · 05-07
今日众生药业(002317)涨停分析:创新药商业化+业绩增长+财务优化驱动
股市必读:众生药业(002317)5月6日董秘有最新回复
证券之星 · 05-07
股市必读:众生药业(002317)5月6日董秘有最新回复
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-06
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
每周股票复盘:众生药业(002317)Q1净利增20.83%
证券之星 · 05-03
每周股票复盘:众生药业(002317)Q1净利增20.83%
众生药业(002317)3月31日股东户数11.1万户,较上期减少2.61%
证券之星 · 04-29
众生药业(002317)3月31日股东户数11.1万户,较上期减少2.61%
图解众生药业年报:第四季度单季净利润同比增长105.62%
证券之星 · 04-29
图解众生药业年报:第四季度单季净利润同比增长105.62%
4月27日众生药业涨5.01%,兴全多维价值混合A基金重仓该股
证券之星 · 04-27
4月27日众生药业涨5.01%,兴全多维价值混合A基金重仓该股
股市必读:众生药业(002317)4月22日董秘有最新回复
证券之星 · 04-23
股市必读:众生药业(002317)4月22日董秘有最新回复
众生药业最新公告:全资子公司富马酸氯马斯汀原料药获上市批准
证券之星 · 04-13
众生药业最新公告:全资子公司富马酸氯马斯汀原料药获上市批准
众生药业:公司正在推进昂拉地韦片的商业化工作
证券之星 · 04-13
众生药业:公司正在推进昂拉地韦片的商业化工作
众生药业:公司暂无相关计划
证券之星 · 04-13
众生药业:公司暂无相关计划
3月27日众生药业涨5.46%,兴全多维价值混合A基金重仓该股
证券之星 · 03-27
3月27日众生药业涨5.46%,兴全多维价值混合A基金重仓该股
股市必读:众生药业(002317)3月24日董秘有最新回复
证券之星 · 03-25
股市必读:众生药业(002317)3月24日董秘有最新回复
众生药业:ZSP1601片IIb期临床试验正在积极推进中
证券之星 · 03-24
众生药业:ZSP1601片IIb期临床试验正在积极推进中
股市必读:众生药业(002317)3月20日董秘有最新回复
证券之星 · 03-23
股市必读:众生药业(002317)3月20日董秘有最新回复
众生药业:公司正在积极推进ZSP1601片IIb期临床试验
证券之星 · 03-20
众生药业:公司正在积极推进ZSP1601片IIb期临床试验
众生药业(002317)披露股东部分股份解除质押公告,3月18日股价上涨1.0%
证券之星 · 03-18
众生药业(002317)披露股东部分股份解除质押公告,3月18日股价上涨1.0%
加载更多
公司概况
公司名称:
广东众生药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-12-11
主营业务:
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。
发行价格:
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":22.54,"timestamp":1778223831000,"preClose":20.49,"halted":0,"volume":40846021,"delay":0,"changeRate":0.1,"floatShares":762000000,"shares":850000000,"eps":0.3447,"marketStatus":"已收盘","change":2.05,"latestTime":"05-08 15:00:00","open":22.54,"high":22.54,"low":22.53,"amount":921000000,"amplitude":0.0005,"askPrice":0,"askSize":0,"bidPrice":22.54,"bidSize":92150,"shortable":0,"etf":0,"ttmEps":0.3447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":20.49,"symbolType":"stock","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":22.54,"lowLimit":18.44,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":4.19,"roa":"--","peRate":65.390194,"roe":"2.43%","epsLYR":0.33,"committee":0,"marketValue":19157000000,"turnoverRate":0.0536,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-05-11。","floatMarketCap":17167000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2633353434","title":"众生药业涨10.00%,开源证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633353434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633353434?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:28","pubTimestamp":1778228899,"startTime":"0","endTime":"0","summary":"今日众生药业(002317)涨10.00%,收盘报22.54元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为79.6%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为信达证券的唐爱金、贺鑫。众生药业(002317)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800028652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633207123","title":"众生药业(002317)披露控股子公司ZSP1601片IIb期临床试验初步结果,5月7日股价上涨9.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633207123","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633207123?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:03","pubTimestamp":1778162597,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,众生药业报收于20.49元,较前一交易日上涨9.98%,最新总市值为174.15亿元。近日,众生药业披露关于控股子公司治疗MASH一类创新药ZSP1601片IIb期临床试验初步结果的公告。公告显示,广东众生药业控股子公司众生睿创自主研发的一类创新药ZSP1601片,在治疗代谢功能障碍相关脂肪性肝炎的IIb期临床试验中取得积极顶线数据。公司将推进与监管部门沟通,计划开展III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633418961","title":"众生药业最新公告:MASH创新药ZSP1601片IIb期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2633418961","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633418961?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:39","pubTimestamp":1778153999,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司控股子公司众生睿创自主研发的MASH一类创新药ZSP1601片IIb期临床试验顶线数据初步分析结果积极。两个剂量组主要疗效终点应答率均显著优于安慰剂组,100mg组、50mg组和安慰剂组应答率分别为64.9%、57.6%和32.5%。ZSP1601片具有逆转肝纤维化潜力,可快速降低肝脏脂肪含量并改善肝酶指标,安全性和耐受性良好。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700036269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","159992","BK1574","06978","BK0077","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138971","title":"今日众生药业(002317)涨停分析:创新药商业化+业绩增长+财务优化驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633138971?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:42","pubTimestamp":1778139767,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业5月7日涨停收盘,收盘价20.49元。今日众生药业涨停的可能因素有:创新药商业化加速,两款一类新药获批上市并纳入医保,昂拉地韦儿童适应症临床积极,RAY1225完成III期入组并获2亿元商业化首付款;2025年成功扭亏为盈,归母净利润2.76亿元、同比增超190%,2026年一季度业绩持续增长;财务结构显著优化,大额有息负债清偿完毕,资产负债率下降,前期冻结资产全部解冻,流动性压力缓解;公司治理合规达标,增强市场信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700020448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","BK1574","BK0188","002317","159992","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633153489","title":"股市必读:众生药业(002317)5月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2633153489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633153489?lang=zh_cn&edition=full","pubTime":"2026-05-07 02:00","pubTimestamp":1778090450,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,众生药业报收于18.63元,上涨1.31%,换手率3.25%,成交量24.78万手,成交额4.61亿元。董秘最新回复投资者: 尊敬的董秘,贵公司一季报出来后,作为1名投资者深感失望,昂拉地韦作为国家1类创新药,贵公司的推广进度实在差强人意,对比青峰药业的流感药,差距明显。投资者: 请问2025年4季度和2026年1季度昂拉地韦的销量和销售收入分别是多小董秘: 您好!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700001344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633907954","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2633907954","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633907954?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:18","pubTimestamp":1778055488,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月06日在投资者关系平台上答复投资者关心的问题。投资者提问:请问2025年4季度和2026年1季度昂拉地韦的销量和销售收入分别是多小众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性高度相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600024251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK0239","BK0188","06978","BK0077","BK1161","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632672268","title":"每周股票复盘:众生药业(002317)Q1净利增20.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632672268","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632672268?lang=zh_cn&edition=full","pubTime":"2026-05-03 04:44","pubTimestamp":1777754651,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,众生药业报收于18.39元,较上周的18.36元上涨0.16%。本周,众生药业4月28日盘中最高价报19.38元。本周关注点来自业绩披露要点:众生药业2026年一季报显示归母净利润9982.3万元,同比上升20.83%。股本股东变化股东户数变动截至2026年3月31日,众生药业股东户数为11.1万户,较2025年12月31日减少2970户,减幅2.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596013","title":"众生药业(002317)3月31日股东户数11.1万户,较上期减少2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596013","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596013?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:52","pubTimestamp":1777456358,"startTime":"0","endTime":"0","summary":"证券之星消息,近日众生药业披露,截至2026年3月31日公司股东户数为11.1万户,较12月31日减少2970.0户,减幅为2.61%。在中药行业个股中,众生药业股东户数高于行业平均水平,截至3月31日,中药行业平均股东户数为5.36万户。从股价来看,2025年12月31日至2026年3月31日,众生药业区间跌幅为3.06%,在此期间股东户数减少2970.0户,减幅为2.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900056166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631176582","title":"图解众生药业年报:第四季度单季净利润同比增长105.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631176582","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631176582?lang=zh_cn&edition=full","pubTime":"2026-04-29 01:32","pubTimestamp":1777397569,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业2025年年报显示,当年度公司主营收入25.23亿元,同比上升2.24%;归母净利润2.76亿元,同比上升192.18%;扣非净利润2.81亿元,同比上升207.97%;其中2025年第四季度,公司单季度主营收入6.34亿元,同比上升13.33%;单季度归母净利润2517.69万元,同比上升105.62%;单季度扣非净利润3546.21万元,同比上升107.9%;负债率19.1%,投资收益1657.76万元,财务费用-526.94万元,毛利率56.12%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900004283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630663643","title":"4月27日众生药业涨5.01%,兴全多维价值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630663643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630663643?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:33","pubTimestamp":1777278797,"startTime":"0","endTime":"0","summary":"证券之星消息,4月27日众生药业涨5.01%,收盘报19.28元,换手率6.03%,成交量45.94万手,成交额8.71亿元。重仓众生药业的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家;过去90天内机构目标均价为23.37。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为兴证全球基金的兴全多维价值混合A。该公募基金现任基金经理为杨世进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629617021","title":"股市必读:众生药业(002317)4月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2629617021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629617021?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:51","pubTimestamp":1776880293,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘,众生药业报收于18.35元,上涨2.57%,换手率3.26%,成交量24.85万手,成交额4.49亿元。董秘最新回复投资者: 规公司的投资者热线长期无人接听,请问公司生产经营是否正常?投关工作人员是否正常履职董秘: 您好!当日关注点来自交易信息汇总:4月22日主力资金净流入4443.62万元,呈现明显吸筹迹象。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300003666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627082435","title":"众生药业最新公告:全资子公司富马酸氯马斯汀原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627082435","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627082435?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:05","pubTimestamp":1776071132,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司全资子公司广东先强药业有限公司近日收到国家药品监督管理局核准签发的富马酸氯马斯汀《化学原料药上市申请批准通知书》。该原料药主要用于治疗过敏性鼻炎、荨麻疹等过敏性疾病。数据显示,富马酸氯马斯汀制剂2025年在中国城市公立医院及实体药店年销售额为6,428万元。此次获批将丰富公司特色原料药产品管线,推进制剂原料药一体化,有利于拓展该品种研发及销售,预期对公司未来业绩提升产生积极影响,但不会对当期经营业绩产生重大影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300021760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627480035","title":"众生药业:公司正在推进昂拉地韦片的商业化工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2627480035","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627480035?lang=zh_cn&edition=full","pubTime":"2026-04-13 15:42","pubTimestamp":1776066124,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业04月13日在投资者关系平台上答复投资者关心的问题。公司始终以科学严谨的态度推进研发与商业化工作。公司正在推进昂拉地韦片的商业化工作,稳步提升产品市场覆盖。同时,公司高度重视药品的国外市场机会,积极寻求国际合作。另外,ZSP1601片IIb期临床试验正在积极推进中。相关进展请以公司公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300015261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627480734","title":"众生药业:公司暂无相关计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2627480734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627480734?lang=zh_cn&edition=full","pubTime":"2026-04-13 15:39","pubTimestamp":1776065944,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司是否有把众生睿创分拆上市的计划?众生药业回复:您好!公司暂无相关计划。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300014678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849367","title":"3月27日众生药业涨5.46%,兴全多维价值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849367","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849367?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:15","pubTimestamp":1774599354,"startTime":"0","endTime":"0","summary":"证券之星消息,3月27日众生药业涨5.46%,收盘报18.53元,换手率4.41%,成交量33.55万手,成交额6.11亿元。重仓众生药业的公募基金请见下表:该股最近90天内共有9家机构给出评级,买入评级8家,增持评级1家;过去90天内机构目标均价为26.02。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为兴证全球基金的兴全多维价值混合A。该公募基金现任基金经理为杨世进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622979770","title":"股市必读:众生药业(002317)3月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2622979770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622979770?lang=zh_cn&edition=full","pubTime":"2026-03-25 02:20","pubTimestamp":1774376427,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘,众生药业报收于17.47元,上涨4.49%,换手率2.9%,成交量22.1万手,成交额3.8亿元。董秘最新回复投资者: 尊敬的董秘您好,贵公司在25年底众生睿创公众号,公布了ZSP1601,2期临床实验者全部完成二次肝穿检查的信息,但目前该信息已经找不到了,不知道公司出于何种原因撤销该信息。ZSP1601片IIb期临床试验正在积极推进中,临床试验研究具有周期长、投入高、风险大的特点,项目具体进展情况请以公司发布的公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500003701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059250","title":"众生药业:ZSP1601片IIb期临床试验正在积极推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059250?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:12","pubTimestamp":1774336336,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业03月24日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘您好,贵公司在25年底众生睿创公众号,公布了ZSP1601,2期临床实验者全部完成二次肝穿检查的信息,但目前该信息已经找不到了,不知道公司出于何种原因撤销该信息。谢谢众生药业回复:您好!ZSP1601片IIb期临床试验正在积极推进中,临床试验研究具有周期长、投入高、风险大的特点,项目具体进展情况请以公司发布的公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400019822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621997743","title":"股市必读:众生药业(002317)3月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2621997743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621997743?lang=zh_cn&edition=full","pubTime":"2026-03-23 01:07","pubTimestamp":1774199230,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,众生药业报收于17.63元,下跌2.6%,换手率2.28%,成交量17.4万手,成交额3.12亿元。董秘最新回复投资者: ZSP1601的IIb阶段数据结果会在一季度公布吗董秘: 您好!公司正在积极推进ZSP1601片IIb期临床试验。如达到相关披露标准,公司将严格根据信息披露规则及时履行信息披露义务,具体请以公司发布的公告为准。当日关注点来自交易信息汇总:3月20日主力资金净流出3951.84万元,散户资金净流入4155.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300000405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620378564","title":"众生药业:公司正在积极推进ZSP1601片IIb期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2620378564","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620378564?lang=zh_cn&edition=full","pubTime":"2026-03-20 15:45","pubTimestamp":1773992710,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)03月20日在投资者关系平台上答复投资者关心的问题。投资者提问:ZSP1601的IIb阶段数据结果会在一季度公布吗众生药业回复:您好!公司正在积极推进ZSP1601片IIb期临床试验。如达到相关披露标准,公司将严格根据信息披露规则及时履行信息披露义务,具体请以公司发布的公告为准。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000023296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620252604","title":"众生药业(002317)披露股东部分股份解除质押公告,3月18日股价上涨1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620252604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620252604?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:24","pubTimestamp":1773843857,"startTime":"0","endTime":"0","summary":"近日,广东众生药业股份有限公司发布公告,公司控股股东、实际控制人张玉冲及持股5%以上股东张玉立于2026年3月17日办理了部分股份解除质押手续。张玉冲解除质押1,678.00万股,占其所持股份比例18.11%,占公司总股本1.97%;张玉立解除质押871.00万股,占其所持股份比例9.40%,占公司总股本1.02%。本次解除质押后,张玉冲累计质押股份891.00万股,占其所持股份9.62%;张玉立累计质押股份446.00万股,占其所持股份4.81%。公司称上述股东质押股份目前不存在平仓风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800040713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778403213186,"stockEarnings":[{"period":"1week","weight":0.2257},{"period":"1month","weight":0.1869},{"period":"3month","weight":0.1488},{"period":"6month","weight":0.079},{"period":"1year","weight":0.9087},{"period":"ytd","weight":0.1876}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"111004人(较上一季度减少2.61%)","perCapita":"6861股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}